Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Eradivir
AddedFeb 18, 2024
UpdatedJun 18, 2026
Eradivir

Eradivir

Angel

Eradivir: A biotech firm developing a non-immunological agent targeting COVID-19 virus.

HQ
West Lafayette, IN, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Eradivir, founded with the mission to combat viral infections, focuses on developing non-immunological targeting agents specifically aimed at the virus causing COVID-19. The company envisions harnessing the human immune system's power to eliminate viruses and virus-infected cells without inducing detrimental immune responses. Their core product is a novel agent that targets and neutralizes the COVID-19 virus, positioning them in the biotech sector with a strong emphasis on innovative antiviral therapies.

Notable figures associated with Eradivir include leading scientists and biotech investors committed to advancing antiviral research. The company has achieved significant milestones, including promising preclinical results and securing crucial funding for further development. Eradivir's impact lies in its potential to offer a groundbreaking treatment option for COVID-19, contributing to global efforts in managing and eventually overcoming the pandemic.

Eradivir - Similar Companies

Exavir Therapeutics logo

Exavir Therapeutics

CoviCept Therapeutics logo

CoviCept Therapeutics

Evrys Bio logo

Evrys Bio

evrys.com

IconOVir Bio logo

IconOVir Bio

iconovir.com

Kovina Therapeutics logo

Kovina Therapeutics

kovina.com

Via Nova Therapeutics logo

Via Nova Therapeutics

vianovatx.com

Virion Therapeutics logo

Virion Therapeutics

viriontx.com

Vir Biotechnology logo

Vir Biotechnology

vir.bio

Antios Therapeutics logo

Antios Therapeutics

Retrovirox logo

Retrovirox

retrovirox.com

Red Queen Therapeutics logo

Red Queen Therapeutics

redqueentx.com

Precision Virologics logo

Precision Virologics

Therabiol logo

Therabiol

EmitBio logo

EmitBio

emitbio.com

Clear Creek Bio logo

Clear Creek Bio

clearcreekbio.com

Eradivir - Quick Facts

Who are Eradivir's competitors?

Companies similar to Eradivir include Exavir Therapeutics, CoviCept Therapeutics, Evrys Bio and IconOVir Bio.

When was Eradivir founded?

Eradivir was founded in 2020.

Where is Eradivir's headquarters located?

Eradivir's headquarters is located in West Lafayette, IN, US.

When was Eradivir's last funding round?

Eradivir's most recent funding round was for $256k (USD) in February 2021.

How much has Eradivir raised to-date?

As of Feb 5, 2021, Eradivir has raised a total of $256k (USD).

How many employees does Eradivir have?

Eradivir has 9 employees as of Feb 4, 2024.

Eradivir - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Antiviral Therapies
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified